NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-30 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-04-02 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-1.82 |
-0.95 |
0.87 |
47.80% |
2023-08-14 |
2023-06 |
-1.8 |
-1.26 |
0.54 |
30.00% |
2023-05-11 |
2023-03 |
-2 |
-2.4 |
-0.4 |
-20.00% |
2023-02-14 |
2022-12 |
-2.2 |
-2.6 |
-0.4 |
-18.18% |
Date |
Name |
Relation |
Quantity |
Description |
2015-02-05 |
ALMENOFF JUNE SHERIE |
Director |
16.90K |
Purchase |
2020-04-29 |
BACKENROTH SAMUEL |
Chief Financial Officer |
11.63K |
Purchase |
2023-03-15 |
BRANNING TODD P |
Chief Financial Officer |
84.20K |
Stock Award(Grant) |
2021-06-17 |
GOLDSTEIN DOV A |
Director |
30.00K |
Purchase |
2017-04-09 |
HIRSCHMAN ORIN |
Director |
0.00 |
Purchase |
2022-03-29 |
MANN WILLIAM ROLAND |
Chief Operating Officer |
11.20K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Armistice Capital, LLC |
166.17K |
310.75K |
7.03% |
2023-06-29 |
Greenlight Capital, Inc. |
136.35K |
254.97K |
5.77% |
2023-06-29 |
Point72 Asset Management, L.P. |
62.50K |
116.88K |
2.65% |
2023-06-29 |
Decheng Capital Management III (Cayman), LLC |
50.00K |
93.50K |
2.12% |
2023-06-29 |
Carnegie Mellon University |
46.97K |
87.83K |
1.99% |
2023-06-29 |
Kestra Advisory Services, LLC |
25.48K |
47.65K |
1.08% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
18.98K |
35.49K |
0.80% |
2023-08-30 |
Jacob Discovery Fd |
15.66K |
15.19K |
0.66% |
2023-05-30 |
Fidelity Extended Market Index Fund |
7.08K |
25.22K |
0.30% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
1.43K |
5.08K |
0.06% |
2023-05-30 |
Fidelity Total Market Index Fund |
1.36K |
4.84K |
0.06% |
2023-07-30 |
Schwab Capital Trust-Total Stock Market Index Fund |
1.49K |
2.06K |
0.06% |
Split |
Date |
1 : 20 |
2023-06-15 |
1 : 20 |
2019-02-04 |
1 : 3 |
2013-06-03 |